Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.

Fiche publication


Date publication

mai 2019

Journal

Journal of hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr BRONOWICKI Jean-Pierre, Dr JOUVE Jean-Louis, Pr MANFREDI Sylvain


Tous les auteurs :
Jouve JL, Lecomte T, Bouché O, Barbier E, Akouz FK, Riachi G, Khac EN, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM,

Résumé

Sorafenib is the reference palliative treatment for hepatocellular carcinoma (HCC). Combining sorafenib with another treatment to improve overall survival (OS) within an acceptable safety profile might be the next step forward. In our view, statins present a particular interest in that respect.

Mots clés

Tyrosine kinase inhibitors, liver cancer, statins

Référence

J. Hepatol.. 2019 May 21;: